Market Intelligence, Clinical Progress, and High-Purity Reagents for Hemoglobinopathy, Ribosome Quality Control, and Stress Granule Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HBS1L drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HBS1L Recombinant Protein: High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active GTPase domain preserved. E. coli or HEK293 expressed. | View HBS1L Products |
| Gene Delivery | HBS1L Promise-ORF/Lentivirus: Full-length ORF with native UTR for stable hematopoietic cell lines. Sequence Verified. | View HBS1L Products |
| Benchmark Ab | Anti-HBS1L Antibody: Recombinant positive control for Western Blot, Flow Cytometry, ICC. C-terminal epitope specific. | View HBS1L Products |
| Validator | HBS1L siRNA Set: Three independent sequences targeting distinct exons. Rescue constructs available. | View HBS1L Products |
| Related Target: MYB | Co-located at HMIP locus; crucial for fetal hemoglobin (HbF) regulation. | View MYB Products |
| Related Target: BCL11A | Downstream repressor of gamma-globin; primary target in sickle cell disease therapies. | View BCL11A Products |
| Related Target: PELO | Pelota Homolog: Direct binding partner in ribosome rescue complex (No-Go Decay). Required for HBS1L-dependent assays. | View PELO Products |
| Related Target: ATRX | Chromatin remodeler co-expressed in erythroid differentiation pathways. | View ATRX Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTPase Biochemical Screening | High-purity recombinant HBS1L with intact functional domains (tr-type G). WT protein and GTPase-dead mutants (T85A/D86N) available as negative controls. |
| Cellular Phenotype Validation (HbF induction) | Lentivirus-mediated stable integration for long-term erythroid differentiation assays. |
| HBS1L-PELO PPI Confirmation | Biotinylated full-length HBS1L for SPR/BLI; native conformation via mild purification. AlphaScreen compatible. |
| Stress Granule Dynamics | Lentivirus particles for stable integration in K562/HEK293T; MOI-optimized for endogenous-level expression. |
| Lack of Reliable Controls | Sequence-verified, Endotoxin-controlled reagents ensure reproducible baseline. |
| Off-Target siRNA Effects | Three independent siRNA sequences included; rescue constructs with silent mutations. |
| Species Cross-Reactivity | Human/Mouse/Rat ortholog proteins with >90% sequence identity, verified by mass spec. |
Live HBS1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for therapies modulating HBS1L and its regulatory network is intensifying. HBS1L (HBS1 Like Translational GTPase) belongs to the tr-type G GTPase family (UniProt Q9Y450 domain) and functions as a translational GTPase involved in ribosome rescue (No-Go Decay, NGD) via its interaction with Pelota (PELO). The HBS1L-MYB intergenic region (HMIP) is one of the strongest known genetic modifiers of fetal hemoglobin (HbF) levels, making HBS1L a highly attractive target for sickle cell disease (SCD) and beta-thalassemia through gene editing, antisense oligonucleotides, or small molecules. Additionally, HBS1L's role in stress granule dynamics and ribosome quality control positions it as a vulnerability in rapidly proliferating cancer cells and ribosomopathies such as Diamond-Blackfan Anemia (DBA) and 5q- syndrome. Known mutations include dbSNP:rs4435957 and a variant found in a patient with developmental disorder of uncertain significance (UniProt VAR_048963, VAR_087990). As first-generation therapies reach the clinic, next-wave R&D is targeting highly specific, non-viral delivery of epigenetic modulators or small molecules designed to derepress HbF safely or inhibit HBS1L-PELO in cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Editing (CRISPR) | Biotech/Academic Consortiums | Sickle Cell Disease, Thalassemia | High-efficiency knockdown/knockout (Lentivirus/siRNA) |
| Small Molecule GTPase Modulators | Early-stage Pharma, Rare Disease Biotechs | Hematologic Disorders, Oncology, Ribosomopathies | GTPase Activity Assays (High-purity recombinant protein, mutant controls) |
| PPI Disruptors (HBS1L-PELO) | Discovery Stage Biotech | Solid Tumors (Stress Granule Inhibition) | AlphaScreen/SPR (Full-length native proteins) |
| Antisense Oligonucleotides | RNA Therapeutics Cos, Rare Disease Programs | Beta-Hemoglobinopathies, ATRX syndrome | Transcriptional Silencing Verification (Benchmark Abs, qPCR) |
| Epigenetic Modulators | Translational Research Institutes | Refractory Anemias | Chromatin Interaction Assays (Native conformation proteins) |
| Chemical Proteomics | Platform Biotechs | Target Discovery | Pure Protein Standards for pull-downs |
Molecular Differentiation & Assay Strategy
Developing best-in-class molecules targeting HBS1L requires addressing critical differentiation factors:
- GTPase selectivity: HBS1L belongs to the TRAFAC class GTPases with high homology to eEF1A. Drugs must achieve high selectivity to avoid global translation toxicity. High-purity recombinant protein with intact tr-type G domain is essential for screening.
- Protein-Protein Interaction: HBS1L-PELO interface is a druggable target. Full-length proteins with native conformation needed for SPR/BLI and AlphaScreen.
- Delivery: For hemoglobinopathies, targeting HSCs requires non-viral delivery (LNP, ASO) with efficient membrane penetration.
- Mechanism validation: Distinguish between GTPase activity inhibition and transcriptional regulation of HbF via HMIP locus.
TarMart provides the critical reagent assets: high-purity proteins (>95%), lentivirus for stable cell models, and biomarker antibodies for flow cytometry and Western blot.